Who Paid My Doc
Raymond Dattilo
Cardiovascular Disease Topeka, KS Medical Doctor
NPI 1710946249 CMS profile 1010040
600 Sw College Ave, Topeka, KS 66606
General payments
$12,973
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Raymond Dattilo of Topeka, KS is reported in the CMS Open Payments database as having received $12,973 across 28 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 85th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $2,033 | 3 | |
| 2021 | General | $6,313 | 5 | |
| 2020 | General | $3,633 | 4 | |
| 2019 | General | $995 | 16 |
Beside peers
- Raymond Dattilo
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Raymond Dattilo were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Raymond Dattilo | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $995 | $450 | $127–$1,392 | $163 |
| 2020 | $3,633 | $242 | $77–$751 | $114 |
| 2021 | $6,313 | $335 | $101–$1,037 | $132 |
| 2022 | $2,033 | $395 | $121–$1,211 | $149 |
| 2023 | $0 | $443 | $136–$1,283 | $160 |
| 2024 | $0 | $450 | $136–$1,323 | $164 |
| 2025 | $0 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
25
Drug cost
$112
Branded share of claims
56%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Clopidogrel Clopidogrel Bisulfate | Brand | 14 | $111 | |
| Diazepam | Generic | 11 | $2 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
28 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Kansas
Bassem Chehab
Cardiovascular Disease · Wichita, KS
Vasvi Singh
Cardiovascular Disease · Overland Park, KS
Joseph Galichia
Cardiovascular Disease · Wichita, KS
Wassim Shaheen
Cardiovascular Disease · Wichita, KS
Layne Reusser
Cardiovascular Disease · Wichita, KS
Aziz Maksoud
Cardiovascular Disease · Wichita, KS
Related records
Cardiovascular Disease in Kansas
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Kansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.